Cancer immunotherapy drugs only work for a minority of patients, but a generic drug now used to increase blood flow may be able to improve those odds, a study by Columbia University Medical Center researchers suggests.
Columbia has one of six new sites launched by the NIH's Breast Cancer and Environment Research Program for prevention and research across the lifespan.
Dr. Andrea Califano has won a two-year $200,000 research grant for neuroendocrine cancer research.
According to a recent study, a microsurgical approach is found to be a safe and effective technique to prevent breast cancer-related lymphedema.
Andrea Califano and his investigative team discover a molecular signaling mechanism underlying a specific type of highly aggressive breast cancer.
KEYTRUDA is an immunotherapy that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, helping the immune system to help detect and fight cancer cells.